Loyal Raises $100M Series C, Led by age1, to Advance the First Canine Longevity Drug

Loyal 在 age1 领投的 C 轮融资中筹集了 1 亿美元，用于推进首个犬类长寿药物的发展。

With participation from Baillie Gifford, Loyal’s latest funding builds on recent regulatory milestones and brings the company closer to market readiness

在Baillie Gifford的参与下，Loyal的最新融资建立在近期的监管里程碑之上，使公司更接近市场准备就绪。

SAN FRANCISCO, February 11, 2026-- Loyal, a clinical-stage animal health company developing lifespan extension drugs for dogs, announced today that it has raised $100M in Series C funding. age1, the next generation of Laura Deming’s Longevity Fund, led the round. Baillie Gifford also participated alongside existing investors, bringing the total investment in Loyal to over $250M since its founding in late 2019..

旧金山，2026年2月11日 —— 致力于开发延长犬类寿命药物的临床阶段动物健康公司Loyal今天宣布，已在C轮融资中筹集了1亿美元。Laura Deming的Longevity Fund下一代基金age1领投了本轮。Baillie Gifford与现有投资者共同参与，使Loyal自2019年底成立以来的总投资额超过了2.5亿美元。

“Our driving purpose at Loyal is to help dogs live longer, healthier lives,” said Loyal Founder & CEO Celine Halioua. “We’re closer than ever to delivering a solution to the problem we set out to solve: an FDA-approved drug for canine lifespan extension. This capital will help our team see our lead program through the remaining FDA requirements and get to market.”.

“我们在Loyal的首要目标是帮助狗活得更长、更健康，”Loyal创始人兼首席执行官塞琳·哈里奥阿表示。“我们比以往任何时候都更接近于提供一个解决方案，解决我们最初设定的问题：一种经FDA批准的用于延长犬类寿命的药物。这笔资金将帮助我们的团队完成主导项目剩余的FDA要求并推向市场。”

LOY-002, a prescription daily pill, is Loyal’s lead program and aims to extend the healthy lifespan of senior dogs by proactively targeting the underlying metabolic drivers of aging. With the Reasonable Expectation of Effectiveness (RXE) and Target Animal Safety (TAS) sections complete, Loyal has satisfied two of the three major requirements for LOY-002’s application for Expanded Conditional Approval (XCA).

LOY-002 是一种处方每日药丸，是 Loyal 公司的主要项目，旨在通过主动针对衰老的潜在代谢驱动因素，延长老年狗的健康寿命。随着“合理有效性预期”（RXE）和“目标动物安全性”（TAS）部分的完成，Loyal 已满足了 LOY-002 申请扩展条件批准（XCA）的三个主要要求中的两个。

If approved, LOY-002 stands to be the first FDA-approved drug for lifespan extension itself in any species..

如果获得批准，LOY-002 将成为首个被 FDA 批准的用于延长任何物种寿命的药物。

“I’ve been incredibly lucky to know Celine since 2018 and to have witnessed and supported the team's relentless execution as an investor,” said Alex Colville, Co-founder and General Partner of age1. “Loyal has created a scientific and cultural movement towards proactive therapeutics for aging. Very few realize the impact this has had to date and the impact it will have to come.

“自2018年以来，我非常幸运能够认识塞琳，并以投资者的身份见证并支持团队的不懈执行，”age1的联合创始人兼普通合伙人亚历克斯·科尔维尔表示。“Loyal开创了一场科学与文化领域的运动，致力于推动针对衰老的前瞻性疗法。很少有人意识到迄今为止这一成就所带来的影响以及未来将会产生的影响。”

The way we understand and approach aging will never be the same.”.

我们对衰老的理解和应对方式将永远不同。

As Loyal continues to advance its first drug and build its portfolio, the new capital will support the company’s efforts to scale its team, build distribution channels, and prepare for market launch of the first drug to extend canine lifespan. The final major requirement for FDA Expanded Conditional Approval (XCA) is in progress, and the company plans to submit it for review later this year..

随着Loyal持续推进其首款药物研发并扩充产品组合，新资金将支持公司扩大团队、建立分销渠道，并为其首款延长犬类寿命的药物上市做准备。美国食品药品监督管理局（FDA）扩大条件性批准（XCA）的最后一个主要要求正在进展中，该公司计划在今年晚些时候提交审核。

“Celine and the team are redefining how preventive care is approached in veterinary medicine,” said Tom Slater, partner at Baillie Gifford. “Helping dogs live longer, healthier lives matters to many families. By combining scientific rigour with a clear regulatory plan, Loyal has the foundations to build a substantial business in a large and expanding market.”.

“Celine 和她的团队正在重新定义兽医学中预防性护理的处理方式，”Baillie Gifford 的合伙人 Tom Slater 表示。“帮助狗活得更久、更健康对许多家庭来说都很重要。通过将科学严谨性与明确的监管计划相结合，Loyal 已具备在庞大且不断扩展的市场中建立实质性业务的基础。”

The financing comes as Loyal has made significant progress in its pursuit of XCA for LOY-002. In the past year, Loyal has completed two of three major requirements needed for LOY-002’s XCA application and market launch and also completed enrollment in its pivotal trial, the STAY study, which is following 1,300 dogs across 70 veterinary clinics nationwide — the largest clinical trial in the history of veterinary medicine.

这笔融资的到来正值Loyal在LOY-002的XCA申请方面取得重大进展之际。在过去一年中，Loyal已经完成了LOY-002的XCA申请和上市所需的三个主要要求中的两个，并且已经完成了其关键试验STAY研究的入组工作，该研究正在全国70家兽医诊所追踪1300只狗，这是兽医学历史上规模最大的临床试验。

Together, these achievements demonstrate the scientific and regulatory rigor of Loyal’s approach to longevity drug development and advance the company towards market readiness..

这些成就共同证明了Loyal在长寿药物开发方面的科学严谨性和监管严格性，并推动公司朝着市场准备就绪的方向迈进。

About Loyal

关于忠诚

Loyal is an animal health company developing the first drugs intended to help dogs live longer, healthier lives. With over $250M raised to date, Loyal hopes to extend the lifespan of dogs and improve their quality of life by targeting the underlying mechanisms of aging. Loyal’s work builds on decades of research, and their team of experts in dog health and longevity is dedicated to furthering this research and developing better ways to quantify and improve the aging process in dogs.

Loyal是一家动物健康公司，正在研发旨在帮助狗更长寿、更健康的首批药物。迄今为止，Loyal已筹集超过2.5亿美元，希望通过针对衰老的潜在机制来延长狗的寿命并改善其生活质量。Loyal的工作基于数十年的研究，他们在狗的健康和长寿领域的专家团队致力于推进这一研究，并开发出更好的方法来量化和改善狗的衰老过程。

It currently has three drugs in development and is making progress toward approval from the FDA’s Center for Veterinary Medicine..

它目前有三种药物正在研发中，并且正在朝着获得美国食品药品监督管理局兽药中心的批准取得进展。

For more information, please visit loyal.com.

欲了解更多信息，请访问 loyal.com。

Contact:

联系人：

Press contact

媒体联系人

Isabelle Wood

伊莎贝尔·伍德

Communications Manager

通讯经理

415-320-6360

415-320-6360

press@loyal.com

press@loyal.com